- Inicio
- pct-off 70-90
- Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
5 (253) · € 12.99 · En stock
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy: Molecular Therapy
Frontiers Emerging roles of the gut microbiota in cancer immunotherapy
Cancers, Free Full-Text
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
Frontiers CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
Gut microbiome and CAR-T therapy, Experimental Hematology & Oncology
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies - Xie - iMeta - Wiley Online Library
The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies, Cell & Bioscience
